PUBLISHER: TechNavio | PRODUCT CODE: 1908411
PUBLISHER: TechNavio | PRODUCT CODE: 1908411
The global myocardial infarction (mi) therapeutics market is forecasted to grow by USD 2314.9 mn during 2025-2030, accelerating at a CAGR of 4.9% during the forecast period. The report on the global myocardial infarction (mi) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global burden of cardiovascular diseases and increasing incidence of myocardial infarction, advancements in drug development and innovation in mi treatment protocols, expanding healthcare infrastructure and improved access to cardiac care.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2026 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 4.5% |
| CAGR | 4.9% |
| Incremental Value | $2314.9 mn |
Technavio's global myocardial infarction (mi) therapeutics market is segmented as below:
By Product
By End-User
By Route Of Administration
Geography
This study identifies the growing integration of precision medicine in mi treatment strategies as one of the prime reasons driving the global myocardial infarction (mi) therapeutics market growth during the next few years. Also, expansion of combination therapy approaches for secondary prevention and rising emphasis on post-acute care and long-term disease management will lead to sizable demand in the market.
The report on the global myocardial infarction (mi) therapeutics market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global myocardial infarction (mi) therapeutics market vendors that include Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol Myers Squibb Co., CeleCor Therapeutics, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Faraday Pharmaceuticals, Idorsia Pharmaceuticals Ltd., Johnson and Johnson Services, Merck and Co. Inc., Mesoblast Ltd., Novartis AG, Pfizer Inc., Sanofi SA. Also, the global myocardial infarction (mi) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.